Browse News
Filter News
Found 588 articles
-
Labcorp Receives FDA Emergency Use Authorization for Mpox PCR Test Home Collection Kit
4/10/2024
Labcorp announced the U.S. Food and Drug Administration has granted Emergency Use Authorization for its Mpox PCR Test Home Collection Kit to aid in the diagnosis of infection with non-variola Orthopoxvirus, including the monkeypox virus that causes monkeypox, also known as mpox.
-
Morris & Dickson is the First U.S. Distributor for Bavarian Nordic’s JYNNEOS®, the Only FDA-approved Mpox Vaccine
4/3/2024
Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic’s newly launched mpox vaccine, JYNNEOS®.
-
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
4/2/2024
Bavarian Nordic A/S announced that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers.
-
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
4/1/2024
SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on health security and infectious disease, announced that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc.
-
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
4/1/2024
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent operational highlights.
-
SIGA Names Larry Miller General Counsel
3/25/2024
SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel.
-
Cue Health Reports Fourth Quarter 2023 Financial Results
3/13/2024
Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023.
-
SIGA Declares Special Cash Dividend of $0.60 Per Share
3/12/2024
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock.
-
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
3/12/2024
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023.
-
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results
3/5/2024
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024.
-
Celebrating Its Fifth Anniversary, Genesis Reference Laboratories Announces Testing Upgrades
2/8/2024
Genesis Reference Laboratories, a leading diagnostics laboratory, is pleased to announce upgrades to its testing menus.
-
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
1/22/2024
SIGA Technologies, Inc. today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company’s Board of Directors.
-
Mpox (Monkeypox) Vaccine Triggers Equally Strong Immune Response in Smaller Than Usual Doses and in People With or Without HIV
12/14/2023
Delivering the two-dose mpox vaccine, called JYNNEOS, in smaller than the usual FDA-approved doses, and by injection between layers of the skin rather than by the standard route under the skin, produced a detectable immune response, a new study shows.
-
Microbix & BioGX Collaborate on real-time PCR Assays & Controls
12/7/2023
Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces a collaboration with BioGX, Inc., a global provider of easy molecular diagnostic solutions.
-
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
11/28/2023
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Single-Ascending Dose part of the Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's broad-spectrum antiviral drug, was completed successfully.
-
U.S. Molecular Diagnostics Market Size To Hit USD 9.78 Bn By 2032
11/22/2023
The U.S. molecular diagnostics market size was exhibited at USD 6.1 billion in 2022 and it is expected to hit around USD 9.78 billion by 2032, growing at a CAGR of 4.83% during the forecast period from 2023 to 2032.
-
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
11/14/2023
IMUNON, Inc. announced financial results for the three and nine months ended September 30, 2023.
-
Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights
11/9/2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent operational highlights.
-
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023
11/7/2023
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three and nine months ended September 30, 2023.
-
Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
11/2/2023
Tonix Pharmaceuticals Holding Corp. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), will conduct a Phase 1 clinical trial with TNX-1800 (recombinant horsepox virus, live vaccine),1 Tonix Pharmaceuticals’ vaccine candidate to protect against COVID-19.